Cargando…

Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants

In July 2014, the Committee on Infectious Diseases (COID) updated their guidance on the use of palivizumab, recommending against use in preterm infants 29 to 35 weeks' gestational age (wGA). A primary data source cited to support this significant change was the low respiratory syncytial virus (...

Descripción completa

Detalles Bibliográficos
Autores principales:	DeVincenzo, John P., Ambrose, Christopher S., Makari, Doris, Weiner, Leonard B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2016
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962937/ https://www.ncbi.nlm.nih.gov/pubmed/26889568 http://dx.doi.org/10.1080/21645515.2015.1115936

Ejemplares similares

Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus
por: Makari, Doris, et al.
Publicado: (2014)

The Underrecognized Burden of Respiratory Syncytial Virus Among Infants Presenting to US Emergency Departments
por: Makari, Doris, et al.
Publicado: (2015)

Modeling the Potential Impact of the 2014 American Academy of Pediatrics Respiratory Syncytial Virus Prophylaxis Guidance on Preterm Infant RSV Outcomes
por: McLaurin, Kimmie K., et al.
Publicado: (2015)

735. Severity and Healthcare Costs of Respiratory Syncytial Virus Hospitalizations in US Preterm Infants Born at 29–34 Weeks Gestation: 2014–2016
por: Goldstein, Mitchell, et al.
Publicado: (2018)

Impact of Respiratory Syncytial Virus–Confirmed Hospitalizations on Caregivers of US Preterm Infants
por: Pokrzywinski, Robin M., et al.
Publicado: (2019)

Respiratory Syncytial Virus Disease in Preterm Infants in the US Born at 32–35 Weeks Gestation Not Receiving Immunoprophylaxis
por: Ambrose, Christopher S., et al.
Publicado: (2014)

Respiratory syncytial virus hospitalization trends in infants with chronic lung disease of infancy, 1998–2008
por: Groothuis, Jessie R, et al.
Publicado: (2011)

Altered gut microbiota in infants is associated with respiratory syncytial virus disease severity
por: Harding, Jeffrey N., et al.
Publicado: (2020)

Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics
por: Krilov, Leonard R., et al.
Publicado: (2020)

Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis
por: Pickles, Raymond J, et al.
Publicado: (2015)

Epidemiology of Respiratory Syncytial Virus Infection in Preterm Infants
por: Resch, Bernhard, et al.
Publicado: (2011)

Viral Specific Factors Contribute to Clinical Respiratory Syncytial Virus Disease Severity Differences in Infants
por: Thompson, Tonya M, et al.
Publicado: (2015)

Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation
por: Simões, Eric A. F., et al.
Publicado: (2016)

Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States
por: Parikh, Rohan C., et al.
Publicado: (2017)

Correction: Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation
por: Simões, Eric A. F., et al.
Publicado: (2016)

740. Impact of the 2014 American Academy of Pediatrics Guidance on Respiratory Syncytial Virus Hospitalization Rates for Preterm Infants <29 Weeks Gestational Age at Birth: 2012–2016
por: Goldstein, Mitchell, et al.
Publicado: (2018)

Respiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review
por: Mauskopf, Josephine, et al.
Publicado: (2016)

Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012–2016
por: Goldstein, Mitchell, et al.
Publicado: (2018)

Approaches to use the WHO respiratory syncytial virus surveillance platform to estimate disease burden
por: Pebody, Richard, et al.
Publicado: (2019)

Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants
por: McLaurin, K K, et al.
Publicado: (2016)

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
por: Shahabi, Ahva, et al.
Publicado: (2017)

Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants
por: Simões, Eric A F, et al.
Publicado: (2020)

Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017
por: Fergie, Jaime, et al.
Publicado: (2020)

Uncovering critical properties of the human respiratory syncytial virus by combining in vitro assays and in silico analyses
por: Beauchemin, Catherine A. A., et al.
Publicado: (2019)

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
por: Abushahin, Ahmad, et al.
Publicado: (2018)

Long-Term Burden and Respiratory Effects of Respiratory Syncytial Virus Hospitalization in Preterm Infants—The SPRING Study
por: Carbonell-Estrany, Xavier, et al.
Publicado: (2015)

Relating plaque morphology to respiratory syncytial virus subgroup, viral load, and disease severity in children
por: Kim, Young-In, et al.
Publicado: (2015)

Insurance Status and the Risk of Severe Respiratory Syncytial Virus Disease in United States Preterm Infants Born at 32–35 Weeks Gestational Age
por: Franklin, Jeremy A., et al.
Publicado: (2016)

Respiratory syncytial virus acute respiratory infection‐associated hospitalizations in preterm Mexican infants: A cohort study
por: Benítez‐Guerra, Daniela, et al.
Publicado: (2020)

Prolonged Seasonality of Respiratory Syncytial Virus Infection among Preterm Infants in a Subtropical Climate
por: Hsu, Chyong-Hsin, et al.
Publicado: (2014)

Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants
por: Blanken, Maarten O., et al.
Publicado: (2017)

IFI27 may predict and evaluate the severity of respiratory syncytial virus infection in preterm infants
por: Gao, Junyan, et al.
Publicado: (2021)

The association between age and the development of respiratory syncytial virus neutralising antibody responses following natural infection in infants
por: Sande, Charles J., et al.
Publicado: (2014)

Effects of non-invasive respiratory support on sleep in preterm infants evaluated by actigraphy
por: Schmidt, Fernanda, et al.
Publicado: (2021)

Cost of Respiratory Syncytial Virus Infections in US Infants: Systematic Literature Review and Analysis
por: Bowser, Diana M, et al.
Publicado: (2022)

Challenges and Opportunities in Developing Respiratory Syncytial Virus Therapeutics
por: Simões, Eric A. F., et al.
Publicado: (2015)

Seasonal peaks and risk factors of respiratory syncytial virus infections related hospitalization of preterm infants in Taiwan
por: Chi, Hsin, et al.
Publicado: (2018)

Respiratory Syncytial Virus Disease: Immunoprophylaxis Policy Review and Public Health Concerns in Preterm and Young Infants
por: Staebler, Suzanne, et al.
Publicado: (2020)

Respiratory Syncytial Virus–Associated Hospitalization Rates among US Infants: A Systematic Review and Meta-Analysis
por: McLaughlin, John M, et al.
Publicado: (2020)

Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review
por: Wegzyn, Colleen, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pdtmh072a17oig8o813pg2ttb0